Also known as: Maridebart cafraglutide
An antibody-peptide drug designed for once-a-month dosing.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Activates GLP-1 receptors while blocking GIP receptors.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Fat loss & weight | B | Human trials (smaller, mixed, or approved outside the US) |
At a glance
- Route
- Subcutaneous monthly
- Half-life
- Weeks (antibody-based)
Reported dosing
Monthly; Phase 3 doses not finalized.
Timing: Once a month.
Cycle: Trial-defined.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- High vomiting rates in Phase 2 without dose escalation
Who should avoid it
- Not available outside trials
Often combined with
None.
Key findings
Monthly dosing is its main difference from current drugs.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open MariTide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.